These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 28568244)

  • 41. An increase in MPC-1- and MPC-1-CD45+ immature myeloma cells in the progressive states of bone marrow plasmacytosis: the revised phenotypic classification of monoclonal marrow plasmacytosis (MOMP-2005).
    Otsuyama K; Asaoku H; Kawano MM
    Int J Hematol; 2006 Jan; 83(1):39-43. PubMed ID: 16443550
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients.
    Basile A; Moschetta M; Ditonno P; Ria R; Marech I; De Luisi A; Berardi S; Frassanito MA; Angelucci E; Derudas D; Specchia G; Curci P; Pavone V; Rossini B; Ribatti D; Bottazzi B; Mantovani A; Presta M; Dammacco F; Vacca A
    J Pathol; 2013 Jan; 229(1):87-98. PubMed ID: 22847671
    [TBL] [Abstract][Full Text] [Related]  

  • 43. IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma.
    Bolomsky A; Hübl W; Spada S; Müldür E; Schlangen K; Heintel D; Rocci A; Weißmann A; Fritz V; Willheim M; Zojer N; Palumbo A; Ludwig H
    Am J Hematol; 2017 Mar; 92(3):269-278. PubMed ID: 28052520
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cell proliferation of myeloma plasma cells: comparison of the blood and marrow compartments.
    Kumar S; Rajkumar SV; Greipp PR; Witzig TE
    Am J Hematol; 2004 Sep; 77(1):7-11. PubMed ID: 15307099
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma.
    Rajkumar SV; Fonseca R; Lacy MQ; Witzig TE; Therneau TM; Kyle RA; Litzow MR; Gertz MA; Greipp PR
    J Clin Oncol; 1999 May; 17(5):1551-7. PubMed ID: 10334543
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma.
    Korthals M; Sehnke N; Kronenwett R; Schroeder T; Strapatsas T; Kobbe G; Haas R; Fenk R
    Biol Blood Marrow Transplant; 2013 Jul; 19(7):1109-15. PubMed ID: 23644045
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Morphologic and cytogenetic variables affect the flow cytometric recovery of plasma cell myeloma cells in bone marrow aspirates.
    Cogbill CH; Spears MD; Vantuinen P; Harrington AM; Olteanu H; Kroft SH
    Int J Lab Hematol; 2015 Dec; 37(6):797-808. PubMed ID: 26224420
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma.
    Mai EK; Hielscher T; Kloth JK; Merz M; Shah S; Raab MS; Hillengass M; Wagner B; Jauch A; Hose D; Weber MA; Delorme S; Goldschmidt H; Hillengass J
    Haematologica; 2015 Jun; 100(6):818-25. PubMed ID: 25795721
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Can flow cytometry of bone marrow aspirate predict outcome of patients with diffuse large B cell lymphoma? A retrospective single centre study.
    Wolach O; Fraser A; Luchiansky M; Shapiro C; Radnay J; Shpilberg O; Lishner M; Lahav M
    Hematol Oncol; 2015 Mar; 33(1):42-7. PubMed ID: 24470400
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic significance of apoptotic index in multiple myeloma patients treated by conventional therapy and novel agents, thalidomide and bortezomib.
    Minarik J; Scudla V; Ordeltova M; Bacovsky J; Pika T; Langova K
    Eur J Haematol; 2009 Dec; 83(6):528-34. PubMed ID: 19624720
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma.
    Heider U; Langelotz C; Jakob C; Zavrski I; Fleissner C; Eucker J; Possinger K; Hofbauer LC; Sezer O
    Clin Cancer Res; 2003 Apr; 9(4):1436-40. PubMed ID: 12684416
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Determination proliferative activity of myeloma cells in histologic material].
    Fabian P; Kren L; Nenutil R
    Cesk Patol; 2004 Apr; 40(2):46-9. PubMed ID: 15233016
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents.
    Majithia N; Rajkumar SV; Lacy MQ; Buadi FK; Dispenzieri A; Gertz MA; Hayman SR; Dingli D; Kapoor P; Hwa L; Lust JA; Russell SJ; Go RS; Kyle RA; Kumar SK
    Leukemia; 2016 Nov; 30(11):2208-2213. PubMed ID: 27211270
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Prognostic significance of morphology in multiple myeloma].
    Al-Sahmani M; Trnavská I; Antošová M; Antošová L; Kissová J; Kaisarová B; Adam Z; Buliková A; Penka M; Hájek R
    Klin Onkol; 2012; 25(2):103-9. PubMed ID: 22533884
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Plasma cell maturity as a predictor of prognosis in multiple myeloma.
    Iriyama N; Miura K; Hatta Y; Uchino Y; Kurita D; Takahashi H; Sakagami H; Sakagami M; Kobayashi Y; Nakagawa M; Ohtake S; Iizuka Y; Takei M
    Med Oncol; 2016 Aug; 33(8):87. PubMed ID: 27383407
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bcl-2 protein expression is not related to short survival in multiple myeloma.
    Ong F; van Nieuwkoop JA; de Groot-Swings GM; Hermans J; Harvey MS; Kluin PM; Kluin-Nelemans JC
    Leukemia; 1995 Jul; 9(7):1282-4. PubMed ID: 7630204
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical significance of the appearance of abnormal protein band in patients with multiple myeloma.
    Jo JC; Yoon DH; Kim S; Lee K; Kang EH; Jang S; Park CJ; Chi HS; Huh J; Park CS; Suh C
    Ann Hematol; 2014 Mar; 93(3):463-9. PubMed ID: 23999647
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma.
    Nair AP; Walker P; Kalff A; Bergin K; Hocking J; Avery S; Curtis DJ; Patil S; Das T; Klarica D; Morgan S; Muirhead J; Gorniak M; Reynolds J; Spencer A
    Bone Marrow Transplant; 2017 Jun; 52(6):839-845. PubMed ID: 28319080
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serum Levels of Soluble FLT3 Ligand in Patients with Active Multiple Myeloma Constitute Marker of Bone Marrow Plasma Cell Proliferative Activity.
    Kokonozaki M; Kanellou P; Pappa CA; Vyzoukaki R; Sarantoulaki S; Stavroulaki E; Kyriakaki S; Alegakis A; Boula A; Alexandrakis MG
    Crit Rev Oncog; 2017; 22(3-4):255-262. PubMed ID: 29604902
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Quantification of bone marrow plasma cell infiltration in multiple myeloma: usefulness of bone marrow aspirate clot with CD138 immunohistochemistry.
    Matsue K; Matsue Y; Kumata K; Usui Y; Suehara Y; Fukumoto K; Fujisawa M; Narita K; Takeuchi M
    Hematol Oncol; 2017 Sep; 35(3):323-328. PubMed ID: 27140172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.